Oxfendazole versus triclabendazole dosing for chronic liver fluke (fascioliasis)
A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis
This compares one- and two-dose oxfendazole regimens to a two-dose triclabendazole regimen for people with chronic Fasciola (liver fluke) infection.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Universidad Peruana Cayetano Heredia NIH-funded |
| Lab location | 1 site (Lima, Peru) |
| Project ID | NIH-11141568 on NIH RePORTER |
What this research studies
If you have chronic Fasciola hepatica infection, this randomized, single-blind trial will assign you to receive either one or two doses of oxfendazole or the standard two-dose triclabendazole regimen. Doctors will monitor parasitological cure and safety after treatment and during follow-up visits. The team has completed animal toxicology studies and human phase 1 work showing oxfendazole is bioavailable and safe, and this trial tests whether oxfendazole works as well as triclabendazole. The work is being led by investigators at Universidad Peruana Cayetano Heredia with sites in endemic areas of Peru.
Who could benefit from this research
Good fit: People (children and adults) with confirmed chronic Fasciola hepatica infection who can attend study visits at the trial sites are ideal candidates.
Not a fit: People without Fasciola infection, or those who cannot take benzimidazole drugs or meet medical exclusion criteria (for example, certain health conditions or pregnancy), may not benefit or be eligible.
Why it matters
Potential benefit: If successful, this could provide an effective and more accessible alternative dosing option to treat fascioliasis and help address emerging triclabendazole resistance.
How similar studies have performed: Triclabendazole is the established treatment but faces reports of resistance, while oxfendazole has shown strong results in animals and phase 1 human safety studies but has not yet been widely tested for human fascioliasis.
Where this research is happening
Lima, Peru
- Universidad Peruana Cayetano Heredia — Lima, Peru (Active)
Researchers
- Principal investigator: Garcia, Hector Hugo — Universidad Peruana Cayetano Heredia
- Study coordinator: Garcia, Hector Hugo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.